Vaccination against COVID‐19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders
Open Access
- 2 March 2021
- journal article
- editorial
- Published by Wiley in Haemophilia
- Vol. 27 (4), 515-518
- https://doi.org/10.1111/hae.14271
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineThe New England Journal of Medicine, 2020
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older AdultsThe New England Journal of Medicine, 2020
- WFH Guidelines for the Management of Hemophilia, 3rd editionHaemophilia, 2020
- COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trialsBiochemical Pharmacology, 2020
- In‐hospital management of persons with haemophilia and COVID‐19: Practical guidanceHaemophilia, 2020
- Three decades of messenger RNA vaccine developmentNano Today, 2019
- Consensus statements on vaccination in patients with haemophilia—Results from the Italian haemophilia and vaccinations (HEVA) projectHaemophilia, 2019
- Vaccinations are not associated with inhibitor development in boys with severe haemophilia AHaemophilia, 2018
- Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia ABlood, 2016
- Guidelines for the management of hemophiliaHaemophilia, 2012